Literature DB >> 15167673

The role of thoracoscopic spinal surgery in the management of pyogenic vertebral osteomyelitis.

Thomas Mückley1, Tanja Schütz, Meic H Schmidt, Michael Potulski, Volker Bühren, Rudolf Beisse.   

Abstract

STUDY
DESIGN: Case report, operative technique.
OBJECTIVES: Vertebral osteomyelitis is frequently associated with elderly and debilitated patients who have significant medical comorbidities. If surgical debridement is contemplated, an open anterior approach like a thoracotomy can be associated with significant complications in this patient population. Thus, patients with vertebral osteomyelitis who need surgery may benefit from minimal invasive techniques that avoid the complications of more extensive open approaches. We performed thoracoscopic spinal surgery in patients with pyogenic vertebral osteomyelitis, attempting to reduce the morbidity attributable to standard open thoracotomy surgery.
METHODS: The technique and results of minimally invasive thoracoscopic spinal surgery for pyogenic vertebral osteomyelitis in three patients, including radical debridement and anterior spinal reconstruction, are presented.
RESULTS: Radical debridement and anterior spinal reconstruction are feasible via endoscopic approach. Standard thoracotomy or thoracoabdominal approaches associated with high morbidity can be avoided, even for fusion across multiple levels. Conversion to open technique was not necessary in this study. There was no recurrence of infection or loss of reduction during the follow-up period. Operative time and blood loss of endoscopic technique were comparable to open technique.
CONCLUSIONS: The cases clearly demonstrate the feasibility and efficacy of thoracoscopic spinal surgery in the management of pyogenic vertebral osteomyelitis. Debridement, decompression of the spinal canal, interbody fusion, and anterior spinal fixation can be performed via endoscopic approach.

Entities:  

Mesh:

Year:  2004        PMID: 15167673     DOI: 10.1097/00007632-200406010-00023

Source DB:  PubMed          Journal:  Spine (Phila Pa 1976)        ISSN: 0362-2436            Impact factor:   3.468


  9 in total

Review 1.  Treatment of spondylodiscitis.

Authors:  Kourosh Zarghooni; Marc Röllinghoff; Rolf Sobottke; Peer Eysel
Journal:  Int Orthop       Date:  2011-12-06       Impact factor: 3.075

2.  Recent advances: infections of the spine.

Authors:  Frank L Acosta; Luis F Galvez; Henry E Aryan; Christopher P Ames
Journal:  Curr Infect Dis Rep       Date:  2006-09       Impact factor: 3.725

Review 3.  Endoscopic surgery on the thoracolumbar junction of the spine.

Authors:  Rudolf Beisse
Journal:  Eur Spine J       Date:  2006-02-11       Impact factor: 3.134

Review 4.  Surgical treatment of pyogenic vertebral osteomyelitis with spinal instrumentation.

Authors:  Wei-Hua Chen; Lei-Sheng Jiang; Li-Yang Dai
Journal:  Eur Spine J       Date:  2006-11-15       Impact factor: 3.134

5.  Anterior debridement and reconstruction via thoracoscopy-assisted mini-open approach for the treatment of thoracic spinal tuberculosis: minimum 5-year follow-up.

Authors:  Guohua Lü; Bing Wang; Jing Li; Weidong Liu; Ivan Cheng
Journal:  Eur Spine J       Date:  2011-10-14       Impact factor: 3.134

Review 6.  Spinal infection: state of the art and management algorithm.

Authors:  Rui M Duarte; Alexander R Vaccaro
Journal:  Eur Spine J       Date:  2013-06-12       Impact factor: 3.134

Review 7.  Pyogenic spondylitis.

Authors:  W Y Cheung; Keith D K Luk
Journal:  Int Orthop       Date:  2011-10-28       Impact factor: 3.075

8.  Minimally invasive thoracic corpectomy: surgical strategies for malignancy, trauma, and complex spinal pathologies.

Authors:  Rohan R Lall; Zachary A Smith; Albert P Wong; Daniel Miller; Richard G Fessler
Journal:  Minim Invasive Surg       Date:  2012-07-24

9.  One-stage surgical management for lumber brucella spondylitis with anterior debridement, autogenous graft, and instrumentation.

Authors:  Xin Hua Yin; Zhong Kai Liu; Bao Rong He; Ding Jun Hao
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.